Skip to Main Content

Paper Details

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
J Clin Oncol
61
2020
Akt, HER2, HER2-positive, HR, HR-negative, HR-negative and HER2-positive breast cancer, Human, Human Epidermal, Human Epidermal Growth Factor Receptor 2, Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers, MK-2206, MammaPrint, PATIENTS, Patients, anthracycline, biomarker, breast cancer, early-stage, hormone receptor, human epidermal growth factor receptor 2, mammalian target, patients, phosphatidylinositol, phosphatidylinositol 3-kinase, rapamycin, rash, taxane
Author NameAffiliation
William F SymmansThe University of Texas, MD Anderson Cancer Center
Richard B SchwabUniversity of California
Teresa HelstenUniversity of California
Rita NandaThe University of Chicago Medical Center
Judy C BougheyMayo Clinic
Claudine IsaacsGeorgetown University
Larissa A KordeNational Cancer Institute
Laura J Van't VeerUniversity of California san francisco
Melissa Paoloni
Melissa Paoloni
Scott M Berry
Christina YauUniversity of California san francisco
Christina YauUniversity of California san francisco
Donald A Berry
  • 1 - 14

Datasets

Release 1.2